Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Ilene Ceil Weitz, MD

    TitleAssociate Professor of Clinical Medicine
    SchoolKeck School of Medicine of USC
    DepartmentMedicine
    Address1441 Eastlake Ave.
    Health Sciences Campus
    Los Angeles California 90033
    Phone+1 323 865 3950
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview
      Dr. Ilene C. Weitz is an Associate Professor of Clinical Medicine at the Keck School of Medicine at the University of Southern California (USC). Her practice sites include, LAC+USC Medical Center, Keck Hospital of USC and USC Norris Cancer Hospital. Dr. Weitz is board certified in Internal Medicine and Hematology.

      Dr. Weitz earned her medical degree at Medical College of Pennsylvania in Philadelphia, followed by an internship and residency in internal medicine at Cedars-Sinai Medical Center. She conducted a fellowship in hematology/oncology at Scripps Clinic and Research Foundation in La Jolla, California.

      Dr. Weitz is a member of the Academy-Simmons College Honor Society, Alpha Omega Alpha, American Medical Womens Association, Los Angeles County Medical Women’s Association, Alumni Associations of Medical College of Pennsylvania and Cedars-Sinai Medical Center, American Society of Hematology, and American Society of Clinical Oncology. She received the Morris Press Humanism Award in 1987 and the “Golden Apple” Outstanding Physician Educator Award in 1990 from Cedars-Sinai Medical Center, as well as the Outstanding Voluntary Faculty Award in the Division of Hematology from USC School of Medicine. Dr Weitz has delivered nationwide lectures and has been published in numerous journals, including American Journal of Clinical Pathology, Hepatology, and Journal of Clinical Oncology, American Journal of Hematology.. She has also contributed eight book chapters or reviews.

      Dr. Weitz’ research and clinical interests include hematologic disorders such as anemias, thrombocytopenia and white blood cell disorders, paroxysmal nocgturnal hemoglobinurua (PNH), immune mediated anemias and thrombocytopenia, thrombosis and hemostasis.


      Collapse Biography 
      Collapse Clinical Trials
      Collapse Awards and Honors
      Simmons College1971Academy Honor Society
      Alpha Omega Alpha1976Elected Member
      Cedars-Sinai Medical Center1987Morris Press Humanism Award
      Cedars-Sinai Medical Center1990Golden Apple Outstanding Physician Educator Award
      Division of Hematology, Keck School of Medicine1996Outstanding Voluntary Faculty

      Collapse ORNG Applications 
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Weitz I, Deloughery T. Effective treatment of chemotherapy induced atypical Haemolytic Uraemic Syndrome: a case series of 7 treated patients. Br J Haematol. 2017 Aug 31. PMID: 28857126.
        View in: PubMed
      2. Liebman HA, Weitz I. Autoimmune Hemolytic Anemia. Med Clin North Am. 2017 Mar; 101(2):351-359. PMID: 28189175.
        View in: PubMed
      3. Piatek CI, Tagawa ST, Wei-Tsai D, Hanna D, Weitz I, O'Connell C, Rochanda L, Groshen S, Liebman HA. OC-14 - Baseline D-dimer levels are predictive of recurrent venous thromboembolism (VTE) at 6 months in cancer patients with VTE treated with tinzaparin. Thromb Res. 2016 Apr; 140 Suppl 1:S174. PMID: 27161687.
        View in: PubMed
      4. Kelly RJ, Höchsmann B, Szer J, Kulasekararaj A, de Guibert S, Röth A, Weitz I, Armstrong E, Risitano AM, Patriquin CJ, Terriou L, Muus P, Hill A, Turner MP, Schrezenmeier H, Peffault de Latour R. Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med. 2015 Sep 10; 373(11):1032-9. PMID: 26352814.
        View in: PubMed
      5. Boonyasampant M, Weitz I, Kay B, Boonchalermvichian C, Liebman HA, Shulman IA. Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab. Transfusion. 2015 Oct; 55(10):2398-403. PMID: 25989361.
        View in: PubMed
      6. Aldoss I, Mark L, Vrona J, Ramezani L, Weitz I, Mohrbacher AM, Douer D. Adding ascorbic acid to arsenic trioxide produces limited benefit in patients with acute myeloid leukemia excluding acute promyelocytic leukemia. Ann Hematol. 2014 Nov; 93(11):1839-43. PMID: 24906216.
        View in: PubMed
      7. Weitz I. Complement the hemostatic system: an intimate relationship. Thromb Res. 2014 May; 133 Suppl 2:S117-21. PMID: 24862131.
        View in: PubMed
      8. Weitz I. Atypical hemolytic uremic syndrome: the role of complement pathway gene mutation analysis. Clin Adv Hematol Oncol. 2014 Apr; 12(4):266-8. PMID: 25003358.
        View in: PubMed
      9. Chaudhary P, Hepgur M, Sarkissian S, Smith RJ, Weitz I. Atypical haemolytic-uraemic syndrome due to heterozygous mutations of CFH/CFHR1-3 and complement factor H 479. Blood Transfus. 2014 Jan; 12(1):111-3. PMID: 24333077; PMCID: PMC3926711.
      10. Raza A, Ravandi F, Rastogi A, Bubis J, Lim SH, Weitz I, Castro-Malaspina H, Galili N, Jawde RA, Illingworth A. A prospective multicenter study of paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure. Cytometry B Clin Cytom. 2014 May; 86(3):175-82. PMID: 24227693.
        View in: PubMed
      11. Raza A, Ravandi F, Rastogi A, Bubis J, Lim SH, Weitz I, Castro-Malaspina H, Galili N, Jawde RA, Illingworth A. A Prospective Multicenter Study of Paroxysmal Nocturnal Hemoglobinuria Cells in Patients with Bone Marrow Failure. Cytometry B Clin Cytom. 2013 Oct 11. PMID: 24127323.
        View in: PubMed
      12. Weitz I, Meyers G, Lamy T, Cahn JY, Uranga MT, García Vela JA, Sanz MA, Severino B, Kelly RJ, Hillmen P, Hill A. Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria. Intern Med J. 2013 Mar; 43(3):298-307. PMID: 22909078.
        View in: PubMed
      13. Weitz I, Razavi P, Rochanda L, Zwicker J, Furie B, Manly D, Mackman N, Green R, Liebman HA. Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation. Thromb Res. 2012 Sep; 130(3):361-8. PMID: 22542362.
        View in: PubMed
      14. Weitz I, Sanz MA, Henry D, Schipperus M, Godeau B, Northridge K, Gleeson M, Danese M, Deuson R. A novel approach to the evaluation of bleeding-related episodes in patients with chronic immune thrombocytopenia. Curr Med Res Opin. 2012 May; 28(5):789-96. PMID: 22494019.
        View in: PubMed
      15. Weitz I. Thrombosis in patients with paroxysmal nocturnal hemoglobinuria. Semin Thromb Hemost. 2011 Apr; 37(3):315-21. PMID: 21455865.
        View in: PubMed
      16. Weitz I. Thrombosis in Paroxysmal Nocturnal Hemoglobinuria - insights into the role of complement in thrombosis. Thromb Res. 2010 Apr; 125 Suppl 2:S106-7. PMID: 20433987.
        View in: PubMed
      17. Arkfeld DG, Weitz I. Immune thrombocytopenia in patients with connective tissue disorders and the antiphospholipid antibody syndrome. Hematol Oncol Clin North Am. 2009 Dec; 23(6):1239-49. PMID: 19932431.
        View in: PubMed
      18. Weitz I, Liebman HA. The role of oral anticoagulants in tumor biology. Semin Thromb Hemost. 2007 Oct; 33(7):695-8. PMID: 18000797.
        View in: PubMed
      19. Oliveira B, Arkfeld DG, Weitz I, Shinada S, Ehresmann G. Successful rituximab therapy of acquired factor VIII inhibitor in a patient with rheumatoid arthritis. J Clin Rheumatol. 2007 Apr; 13(2):89-91. PMID: 17414538.
        View in: PubMed
      20. Weitz I. Treatment of immune thrombocytopenia associated with interferon therapy of hepatitis C with the anti-CD20 monoclonal antibody, rituximab. Am J Hematol. 2005 Feb; 78(2):138-41. PMID: 15682410.
        View in: PubMed
      21. Sutherland DE, Weitz I, Liebman HA. Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol. 2003 Jan; 72(1):43-52. PMID: 12508268.
        View in: PubMed
      22. Presant CA, Jacobson J, Wolf W, Waluch V, Weitz I, Macdonald JS. Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)? A Southwest Oncology Group study. Invest New Drugs. 2002 Nov; 20(4):369-76. PMID: 12448653.
        View in: PubMed
      23. Weitz I, Israel VK, Waisman JR, Presant CA, Rochanda L, Liebman HA. Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation. Thromb Haemost. 2002 Aug; 88(2):213-20. PMID: 12195692.
        View in: PubMed
      24. Presant CA, Wolf W, Waluch V, Wiseman CL, Weitz I, Shani J. Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose methotrexate: An in vivo human study using noninvasive (19)F-magnetic resonance spectroscopy. J Clin Oncol. 2000 Jan; 18(2):255-61. PMID: 10637237.
        View in: PubMed
      25. Weitz I, Israel VK, Liebman HA. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. Cancer. 1997 May 15; 79(10):2024-7. PMID: 9149031.
        View in: PubMed
      26. Weitz I, Liebman HA. Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology. 1993 Oct; 18(4):990-7. PMID: 8406374.
        View in: PubMed
      27. Liebman HA, Carfagno MK, Weitz I, Berard P, Diiorio JM, Vosburgh E, Simms RW. Excessive fibrinolysis in amyloidosis associated with elevated plasma single-chain urokinase. Am J Clin Pathol. 1992 Nov; 98(5):534-41. PMID: 1485607.
        View in: PubMed